Perspective Therapeutics (CATX) said Friday its updated interim findings from phase 1/2a study of radiopharmaceutical therapy for advanced neuroendocrine tumors have shown continued patient safety and early signs of efficacy, supporting further dose-finding research.
Nine patients with unresectable or metastatic somatostatin receptor type 2-expressing tumors completed treatment as of Jan. 10, the company said.
Perspective Therapeutics said no dose-limiting toxicities or severe adverse events emerged, and there was no reported decline in renal function, adding that hematologic side effects, such as reduced lymphocyte counts and mild anemia, were limited to grades 1 and 2.
The trial is ongoing at multiple sites for patients who have not previously received radiopharmaceutical therapy and whose disease progressed in the past year, it added.
Shares of the company were up about 4.1% in recent trading.
Price: 3.78, Change: +0.15, Percent Change: +4.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。